Marine natural products extracted from sponges represent a new source for drug discovery. Among marine organisms, the phylum Porifera is the most prolific for the production of pharmacologically active compounds, which are characterized by unique chemical structures [1]. Potential drug discovery targets include matrix metalloproteinases (MMPs), and in particular gelatinases A (MMP-2) and B (MMP-9), which are involved at different levels in the pathogenesis of several human diseases [2]. We used a simple method for preparing aqueous extracts from the Mediterranean demosponge Tethya meloni [3], which allowed the extraction of water-soluble compounds by homogenization of sponge tissue in phosphate buffered saline [4]. The analysis by SDS-PAGE showed a very rich protein pattern. Using a well-known in vitro model represented by lipopolysaccharides (LPS)-activated rat astrocytes, we demonstrated the capability of the sponge extract to inhibit the activity of MMP-2 and MMP-9 in a dose-dependent manner. In particular, astrocytes treated with the crude extract at the higher non-cytotoxic concentration of 60 µg/ml showed a 50% inhibition of MMP-2 and a 70% inhibition of MMP-9 in comparison with the positive control (LPS-activated astrocytes). To identify the bioactive compounds with anti-MMP activity, the crude extract was subjected to anion-exchange chromatography and the pools obtained by the different protein peaks were tested on LPS-activated astrocytes. We identified one fraction, which contains a major protein band of 30 kDa, which exhibited an 80% inhibition towards both MMP-2 and MMP-9, in comparison to positive control. In an effort aimed at the identification of the bioactive compounds with anti-MMP activity, this fraction was subjected to 2-D electrophoresis. Results indicated the presence of about 10 spots at pI between 4.5 and 9.5; probably isoforms of the same protein. The identification of protein, which might be used for pharmaceutical applications, is now in course by MS-MS analysis.
Bioassay-guided identification of bioactive protein compounds from the Mediterranean demosponge Tethya meloni.
ROSSANO, Rocco;
2016-01-01
Abstract
Marine natural products extracted from sponges represent a new source for drug discovery. Among marine organisms, the phylum Porifera is the most prolific for the production of pharmacologically active compounds, which are characterized by unique chemical structures [1]. Potential drug discovery targets include matrix metalloproteinases (MMPs), and in particular gelatinases A (MMP-2) and B (MMP-9), which are involved at different levels in the pathogenesis of several human diseases [2]. We used a simple method for preparing aqueous extracts from the Mediterranean demosponge Tethya meloni [3], which allowed the extraction of water-soluble compounds by homogenization of sponge tissue in phosphate buffered saline [4]. The analysis by SDS-PAGE showed a very rich protein pattern. Using a well-known in vitro model represented by lipopolysaccharides (LPS)-activated rat astrocytes, we demonstrated the capability of the sponge extract to inhibit the activity of MMP-2 and MMP-9 in a dose-dependent manner. In particular, astrocytes treated with the crude extract at the higher non-cytotoxic concentration of 60 µg/ml showed a 50% inhibition of MMP-2 and a 70% inhibition of MMP-9 in comparison with the positive control (LPS-activated astrocytes). To identify the bioactive compounds with anti-MMP activity, the crude extract was subjected to anion-exchange chromatography and the pools obtained by the different protein peaks were tested on LPS-activated astrocytes. We identified one fraction, which contains a major protein band of 30 kDa, which exhibited an 80% inhibition towards both MMP-2 and MMP-9, in comparison to positive control. In an effort aimed at the identification of the bioactive compounds with anti-MMP activity, this fraction was subjected to 2-D electrophoresis. Results indicated the presence of about 10 spots at pI between 4.5 and 9.5; probably isoforms of the same protein. The identification of protein, which might be used for pharmaceutical applications, is now in course by MS-MS analysis.File | Dimensione | Formato | |
---|---|---|---|
Planta Med 2016.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
DRM non definito
Dimensione
356.84 kB
Formato
Adobe PDF
|
356.84 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.